U.S. markets closed
  • S&P 500

    4,567.00
    -88.27 (-1.90%)
     
  • Dow 30

    34,483.72
    -652.22 (-1.86%)
     
  • Nasdaq

    15,537.69
    -245.14 (-1.55%)
     
  • Russell 2000

    2,198.91
    -43.07 (-1.92%)
     
  • Crude Oil

    67.00
    -2.95 (-4.22%)
     
  • Gold

    1,773.30
    -9.00 (-0.50%)
     
  • Silver

    22.79
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1340
    +0.0047 (+0.42%)
     
  • 10-Yr Bond

    1.4430
    -0.0870 (-5.69%)
     
  • GBP/USD

    1.3304
    -0.0008 (-0.06%)
     
  • USD/JPY

    113.1450
    -0.4630 (-0.41%)
     
  • BTC-USD

    57,460.69
    -781.90 (-1.34%)
     
  • CMC Crypto 200

    1,456.40
    +13.62 (+0.94%)
     
  • FTSE 100

    7,059.45
    -50.50 (-0.71%)
     
  • Nikkei 225

    27,821.76
    -462.16 (-1.63%)
     

Orchard Therapeutics' MPS-I Gene Therapy Shows Encouraging Action In Early Study, Shares Spike

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Orchard Therapeutics Plc (NASDAQ: ORTX) gains in premarket in reaction to positive interim data from a proof-of-concept study evaluating its gene therapy OTL-203 in Mucopolysaccharidosis type I (MPS-I). All eight patients treated with OTL-203 showed stable cognitive function, motor function, and growth within the normal range at multiple data points post-treatment.

  • OTL-203 treatment demonstrated rapid and sustained metabolic correction with all patients achieving supra-physiological IDUA expression in dried blood spot samples at 12 months (a primary efficacy endpoint).

  • FDA and European Medicines Agency (EMA) have accepted Orchard's request for parallel scientific advice to seek feedback in advance of initiating a registrational study for OTL-203 by this year-end.

  • The company also announced encouraging preliminary biomarker data for OTL-201 in three Mucopolysaccharidosis type IIIA (MPS-IIIA) patients, showing promising tolerability, engraftment, and biomarker data over the initial three-month follow-up period. Recently, a fourth patient was enrolled in the study. The enrollment could complete (n=5) this year, and additional interim data expected later this year.

  • IR webinar is scheduled today at 4:30 p.m. ET to review OTL-203 and OTL-201 data.

  • Last year in December, the company received its first product approval for Libmeldy in Europe for eligible patients with early-onset metachromatic leukodystrophy.

  • Price Action: ORTX jumped 10% at $8.31 in premarket trading on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.